Nasmed Özel Saglik Hizmetleri Ticaret Anonim Sirketi Past Earnings Performance
Past criteria checks 0/6
Nasmed Özel Saglik Hizmetleri Ticaret Anonim Sirketi's earnings have been declining at an average annual rate of -50.1%, while the Healthcare industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 54.5% per year.
Key information
-50.1%
Earnings growth rate
-51.0%
EPS growth rate
Healthcare Industry Growth | 58.3% |
Revenue growth rate | 54.5% |
Return on equity | -7.7% |
Net Margin | -13.3% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Nasmed Özel Saglik Hizmetleri Ticaret Anonim Sirketi makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 693 | -92 | 85 | 0 |
31 Mar 24 | 669 | -44 | 86 | 0 |
31 Dec 23 | 617 | 92 | 72 | 0 |
30 Sep 23 | 805 | 19 | 92 | 0 |
30 Jun 23 | 734 | 0 | 83 | 0 |
31 Mar 23 | 616 | -45 | 59 | 0 |
31 Dec 22 | 499 | -146 | 47 | 0 |
30 Sep 22 | 230 | 7 | 20 | 0 |
30 Jun 22 | 208 | 17 | 17 | 0 |
31 Mar 22 | 189 | 15 | 16 | 0 |
31 Dec 21 | 170 | 17 | 13 | 0 |
30 Sep 21 | 157 | 37 | 11 | 0 |
30 Jun 21 | 144 | 35 | 11 | 0 |
31 Mar 21 | 130 | 38 | 9 | 0 |
31 Dec 20 | 115 | 33 | 9 | 0 |
Quality Earnings: EGEPO is currently unprofitable.
Growing Profit Margin: EGEPO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EGEPO is unprofitable, and losses have increased over the past 5 years at a rate of 50.1% per year.
Accelerating Growth: Unable to compare EGEPO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EGEPO is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (6.2%).
Return on Equity
High ROE: EGEPO has a negative Return on Equity (-7.7%), as it is currently unprofitable.